/






























Discover how PaxVax vaccinations can help protect your patients from typhoid and cholera while traveling.1,2

Watch the full video experience to get a CDC Yellow Book.*

*Conditions apply. Please see details below.

Thank you for learning more about typhoid and cholera.

Now that you know more about the risk and prevalence of these diseases, know that you can help protect your patients by prescribing Vaxchora® (Cholera Vaccine, Live, Oral) and Vivotif® (Typhoid Vaccine Live Oral Ty21a) vaccines.1,2

Please provide your contact information so we can send you your copy of the CDC Yellow Book as a handy reference about vaccine recommendations.

Cholera and typhoid are more prevalent than you might imagine.3,4 Of the top 20 international destinations frequented by U.S. travelers, five are cholera-endemic countries, including the Dominican Republic, Jamaica, China, India, and the Philippines.3,5 Additionally, in recent years there has been a rapid spread and re-emergence of cholera in the Americas, with cases reported in Cuba, Mexico, Ecuador, and Haiti.3 Typhoid fever is also endemic in many countries worldwide, and even short-term travel to high-incidence areas is associated with risk for typhoid fever.4

Travelers have trouble following food and water safety precautions.6

98% of the 688 international travelers who completed a voluntary follow-up survey failed to adhere to food and water precautions in the first 3 days of their stay abroad.6

Make sure your patients are protected.

Travel vaccinations may be a critical part of travel planning for your patients.7 PaxVax is a leading independent vaccine company dedicated to developing and commercializing specialty vaccines that help protect against existing and emerging infectious diseases.

Learn more about typhoid and cholera vaccines

Make sure your patients are protected.

You know the importance of counseling patients who go abroad about practicing good hygiene, eating only well-cooked food, and taking precautions with drinking water to protect themselves from cholera and typhoid.3,4 But there’s even more you can do to help keep your patients safe. Travel vaccinations may also be another critical part of travel planning.5

Get your copy of the CDC Yellow Book*

The Centers for Disease Control and Prevention (CDC) Yellow Book is published every two years as a reference for healthcare providers caring for international travelers. The fully revised and updated CDC Yellow Book 2018 codifies the CDC’s most current travel health guidelines, including:

  • Pretravel vaccine recommendations
  • Destination-specific health advice
  • Helpful maps showing disease prevalence by region
  • And more

Offer good while supplies last. Void where prohibited, licensed, or restricted by federal, state, provincial, or local laws or regulation or agency/institutional policy. Other restrictions may apply.

SIGN UP

 
*Required fields

SIGN UP

Vivotif®

(Typhoid Vaccine Live Oral Ty21a)

Important Safety Information1

Vivotif (Typhoid Vaccine Live Oral Ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by Salmonella Typhi. Routine typhoid vaccination is not recommended in the United States of America. Selective immunization against typhoid fever is recommended for the following groups:  1) travelers to areas in which there is a recognized risk of exposure to  S  Typhi; 2) persons with intimate exposure (eg, household contact) to an  S  Typhi carrier; and 3) microbiology laboratorians who work frequently with  S  Typhi. There is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters, or in persons attending rural summer camps.

Vivotif (Typhoid Vaccine Live Oral Ty21a) should not be administered to persons with a hypersensitivity to any component of the vaccine or the enteric-coated capsule. The vaccine should not be administered to persons during an acute febrile illness. Safety of the vaccine has not been demonstrated in persons deficient in their ability to mount a humoral or cell-mediated immune response, due to either a congenital or acquired immunodeficient state including treatment with immunosuppressive or antimitotic drugs. The vaccine should not be administered to these persons regardless of benefits.

Vivotif is not to be taken during an acute gastrointestinal illness. The vaccine should not be administered to individuals receiving sulfonamides and antibiotics since these agents may be active against the vaccine strain and prevent a sufficient degree of multiplication to occur in order to induce a protective immune response. Postpone taking the vaccine if persistent diarrhea or vomiting is occurring. Unless a complete immunization schedule is followed, an optimum immune response may not be achieved. Not all recipients of Vivotif will be fully protected against typhoid fever. Vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms, ie, travelers should take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water.

The health care provider should take all necessary precautions to ensure safe and effective use of the vaccine. Patients should be questioned about previous reactions to this or similar products. The previous immunization history of the patient and current antibiotic usage should be obtained by the health care provider.

Please see full Prescribing Information.

Vaxchora®

(Cholera Vaccine, Live, Oral)

Important Safety Information2

Vaxchora is contraindicated in people with a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of Vaxchora or to a previous dose of any cholera vaccine.

The safety and effectiveness of Vaxchora have not been established in immunocompromised persons.

Vaxchora may be shed in the stool of recipients for at least 7 days. There is a potential for transmission of the vaccine strain to non-vaccinated close contacts (e.g., household contacts). Use caution when considering whether to administer Vaxchora to individuals with immunocompromised close contacts.

The most common adverse reactions (incidence >3%) were tiredness (31%), headache (29%), abdominal pain (19%), nausea/vomiting (18%), lack of appetite (17%), and diarrhea (4%).

Indications and Usage2

Vaxchora is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.

Limitations of Use: The effectiveness of Vaxchora has not been established in persons living in cholera-affected areas. The effectiveness of Vaxchora has not been established in persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. Vaxchora has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.

For more information about Vaxchora, please see full Prescribing Information.

References

  1. Vivotif (Typhoid Vaccine Live Oral Ty21a) [package insert]. Thörishaus, Switzerland: PaxVax Berna GmbH; 2015.
  2. Vaxchora [package insert]. Hamilton, Bermuda: PaxVax Bermuda Ltd.; 2016.
  3. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015; 9(6):1-13
  4. Centers for Disease Control and Prevention, Chapter 3, Infectious Diseases Related to Travel, Typhoid & Paratyphoid Fever. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/typhoid-paratyphoid-fever. Updated May, 2017. Accessed July 11, 2018.
  5. National Travel and Tourism Office. Top Destinations of U.S. Residents Traveling Abroad 2015-2016. https://travel.trade.gov/outreachpages/download_data_table/2015_Outbound_Profile.pdf. Accessed July 11, 2018.
  6. Kozicki M, Steffen R, Schär M. 'Boil it, cook it, peel it or forget it': does this rule prevent travellers' diarrhoea? Int J Epidemiol. 1985;14(1):169-172.
  7. Centers for Disease Control and Prevention. Travelers’ Health. https://wwwnc.cdc.gov/travel/page/yellowbook-home. Updated July 31, 2017. Accessed July 12, 2018.
  1. Vivotif (Typhoid Vaccine Live Oral Ty21a) [package insert]. Thörishaus, Switzerland: PaxVax Berna GmbH; 2015.
  2. Vaxchora [package insert]. Hamilton, Bermuda: PaxVax Bermuda Ltd.; 2016.
  3. Centers for Disease Control and Prevention, Cholera. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/cholera. Updated May 31, 2017. Accessed July 12, 2018.
  4. Centers for Disease Control and Prevention, Typhoid-Paratyphoid Fever. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/typhoid-paratyphoid-fever.
  5. Centers for Disease Control and Prevention. Travelers’ Health. https://wwwnc.cdc.gov/travel/page/yellowbook-home. Updated July 31, 2017. Accessed July 12, 2018.